Literature DB >> 30844553

Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid.

Eric H Kowalski1, Diana Kneibner1, Khalaf Kridin2, Kyle T Amber3.   

Abstract

Bullous pemphigoid and pemphigus constitute two major autoimmune blistering diseases (AIBD) with complicated disease pathomechanisms involving a multitude of cytokines and immunological pathways. The purpose of our literature review of the cytokines and chemokines involved in these AIBDs was to allow for a meta-analysis of studies detailing differential cytokine and chemokine changes in these conditions. Elucidation of inflammatory pathways could lead to more targeted therapies, several of which specific monoclonal antibodies already exist and are used safely for other autoimmune diseases. A systematic review of the Pubmed/Medline database was performed for articles characterizing cytokines/chemokines involved in BP and pemphigus. Further, a meta-analysis was carried out using standardized methods, including assessment for heterogeneity. The results of our analysis demonstrated numerous inflammatory alterations in these AIBDs. Significant alterations included serum levels of IL-5, IL-6, IL-8, IL-17, CCL-17, and CCL-26 in patients with BP, and increased blister fluids levels of IL-5, IL-6, IL-8, CCL11, and TNF-α. Blister fluid levels of IL-1α are decreased in BP. In pemphigus, we identified significantly increased serum levels of IL-10, IL-17, and CCL17. We have additionally summarized all studies excluded from meta-analysis to provide a comprehensive summary of cytokine/chemokine alterations in these two conditions.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bullous pemphigoid; Chemokine; Cytokines; Pemphigus foliaceus; Pemphigus vulgaris

Mesh:

Substances:

Year:  2019        PMID: 30844553     DOI: 10.1016/j.autrev.2019.03.009

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  13 in total

1.  Efficacy and safety of a bioadhesive gel containing propolis extract, nanovitamin C and nanovitamin E on desquamative gingivitis: a double-blind, randomized, clinical trial.

Authors:  José González-Serrano; Julia Serrano; Mariano Sanz; Jesús Torres; Gonzalo Hernández; Rosa María López-Pintor
Journal:  Clin Oral Investig       Date:  2022-07-28       Impact factor: 3.606

2.  Inhibition of dipeptidyl-peptidase 4 induces upregulation of the late cornified envelope cluster in keratinocytes.

Authors:  Lei Bao; Jing Li; Bethany E Perez White; Payal M Patel; Kyle T Amber
Journal:  Arch Dermatol Res       Date:  2021-06-05       Impact factor: 3.033

3.  Characterizing the proteome of bullous pemphigoid blister fluid utilizing tandem mass tag labeling coupled with LC-MS/MS.

Authors:  Farzan Solimani; Dario Didona; Jing Li; Lei Bao; Payal M Patel; Giulia Gasparini; Khalaf Kridin; Emanuele Cozzani; Michael Hertl; Kyle T Amber
Journal:  Arch Dermatol Res       Date:  2021-06-21       Impact factor: 3.033

Review 4.  The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.

Authors:  Kelly N Messingham; Tyler P Crowe; Janet A Fairley
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

5.  Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.

Authors:  Dario Didona; Luca Scarsella; Milad Fehresti; Farzan Solimani; Hazem A Juratli; Manuel Göbel; Stefan Mühlenbein; Lily Holiangu; Josquin Pieper; Vera Korff; Thomas Schmidt; Cassian Sitaru; Rüdiger Eming; Michael Hertl; Robert Pollmann
Journal:  Front Immunol       Date:  2021-03-25       Impact factor: 7.561

6.  IL-13 Genetic Susceptibility to Bullous Pemphigoid: A Potential Target for Treatment and a Prognostic Marker.

Authors:  Yiman Wang; Xuming Mao; Yangchun Liu; Yuyan Yang; Hongzhong Jin; Li Li
Journal:  Front Immunol       Date:  2022-01-24       Impact factor: 7.561

Review 7.  A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy.

Authors:  Payal M Patel; Virginia A Jones; Christy T Behnam; Giovanni Di Zenzo; Kyle T Amber
Journal:  Antibodies (Basel)       Date:  2021-05-17

8.  Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?

Authors:  Roberto Russo; Emanuele Cozzani; Giulia Gasparini; Aurora Parodi
Journal:  Dermatol Ther       Date:  2020-01-02       Impact factor: 2.851

9.  Patients with pemphigus are at an increased risk of developing rheumatoid arthritis: a large-scale cohort study.

Authors:  Khalaf Kridin; Virginia A Jones; Payal M Patel; Shira Zelber-Sagi; Christoph M Hammers; Giovanni Damiani; Kyle T Amber; Arnon D Cohen
Journal:  Immunol Res       Date:  2020-11-07       Impact factor: 2.829

10.  Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?

Authors:  Anna Zakrzewicz; Celina Würth; Benedikt Beckert; Simon Feldhoff; Katrien Vanderheyden; Stian Foss; Jan Terje Andersen; Hans de Haard; Peter Verheesen; Vladimir Bobkov; Ritva Tikkanen
Journal:  Cells       Date:  2022-03-10       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.